PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33033903-7	2020	The impact of UGT2B15 polymorphisms on the pharmacokinetics of oxazepam and lorazepam was simulated and glucuronide metabolites were also simulated for all four drugs.	Lorazepam	76-85	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	14-21	
30921829-5	2019	Furthermore, we found some drug models within the SimCYP  library can be improved, e.g., the minor allele frequency of ABCG2 and the fraction metabolized by UGT2B15 should be incorporated for rosuvastatin and lorazepam, respectively.	Lorazepam	209-218	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	157-164	
30443442-0	2018	The Relationship of UGT2B15 Pharmacogenetics and Lorazepam for Anxiety.	Lorazepam	49-58	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	20-27	
27622723-0	2016	Implication of UGT2B15 Genotype Polymorphism on Postoperative Anxiety Levels in Patients Receiving Lorazepam Premedication.	Lorazepam	99-108	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	15-22	
27622723-2	2016	The UGT2B15 genotype is of importance for the metabolism of lorazepam.	Lorazepam	60-69	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	4-11	
27622723-3	2016	The clinical effect of genetic polymorphisms in UGT2B15 genotype on the treatment of anxiety levels in same-day surgery patients receiving lorazepam, however, is unknown.	Lorazepam	139-148	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	48-55	
27622723-10	2016	Striking was that females with high preoperative anxiety scores and genetically reduced lorazepam glucuronidation (UGT2B15*2 homozygotes) showed more postoperative anxiety reduction than males with the same genotype.	Lorazepam	88-97	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	115-122	
27622723-11	2016	CONCLUSIONS: UGT2B15 genotype contributes to postoperative anxiety reduction after lorazepam premedication.	Lorazepam	83-92	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	13-20	
15961980-0	2005	Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers.	Lorazepam	111-120	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	14-21	
17687269-6	2008	Our study suggests that the UGT2B7 genotype probably affects lorazepam-valproate pharmacodynamic interaction, especially in subjects who have homovariant genotypes of UGT2B7 and UGT2B15, although the effects on the pharmacokinetics are less significant.	Lorazepam	61-70	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	178-185	
15961980-9	2005	CONCLUSIONS: Our results suggest that the UGT2B15*2 polymorphism is a major determinant of interindividual variability with respect to the pharmacokinetics and pharmacodynamics of lorazepam.	Lorazepam	180-189	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	42-49